Priors rates this Established — 90 out of 100, updated weekly. Yes — this looks well established. On the claim that avelumab maintenance therapy extends overall survival compared to best supportive care in patients with advanced urothelial carcinoma that has not progressed on first-line platinum-based chemotherapy, its four-agent AI review panel weighs 3 primary peer-reviewed studies.
How we got this answer. Priors runs each claim through a panel of four AI agents, each acting as a specialist expert reviewer. They read the published, peer-reviewed studies behind the question, judge how strong, consistent and reliable the evidence is, and turn that judgment into a single rating from 0 to 100 — refreshed every week as new studies appear, so it reflects where the evidence stands today, not a one-off verdict.
The traceable studies behind this rating — and the panel’s single strongest counter-argument to it — are in Priors’ full Immune Checkpoint Inhibition Solid Tumours review.